Ozempic® is an FDA-approved once-weekly injectable semaglutide pen manufactured by Novo Nordisk. FDA approved Ozempic® in December 2017 for the treatment of type 2 diabetes; it is not FDA-approved for weight loss (the FDA-approved semaglutide product for chronic weight management is Wegovy®). Weight Method does not dispense or prescribe brand-name Ozempic®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded semaglutide is not FDA-approved.
From 2,000+ patients · Ozempic is already seeing results
Ozempic (semaglutide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Ozempic — it offers compounded semaglutide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.
Key Fact
Ozempic® (semaglutide 0.25-2mg) is an FDA-approved injectable manufactured by Novo Nordisk for type 2 diabetes (approved December 2017). The SUSTAIN clinical-trial program of brand-name Ozempic® reported weight changes of approximately 10-15% in subgroups (FDA labeling). Weight Method's compounded semaglutide program is dispensed at $154/month and is not FDA-approved.
Source: FDA approval data; SUSTAIN clinical trials
Ozempic® (brand-name semaglutide) activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve insulin sensitivity. Per FDA labeling, weight changes of approximately 10-15% have been reported in SUSTAIN-trial subgroups of brand-name Ozempic®.
Ozempic works by mimicking GLP-1 (glucagon-like peptide-1), a natural hormone released after eating that signals satiety to the brain. By binding to GLP-1 receptors in the hypothalamus, Ozempic reduces appetite, decreases food cravings, and helps patients feel full on smaller portions. It also slows gastric emptying, keeping food in the stomach longer and extending the sensation of fullness between meals. Additionally, Ozempic improves insulin sensitivity and helps regulate blood sugar levels, which is why it remains a cornerstone treatment for type 2 diabetes management.
FDA-approved for type 2 diabetes management (2017). The FDA-approved semaglutide product for chronic weight management is Wegovy®.
Ozempic is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is not FDA-approved for weight loss specifically -- that indication belongs to Wegovy, which contains the same active ingredient (semaglutide) at higher doses. However, physicians frequently prescribe Ozempic off-label for weight management in patients who meet clinical criteria, and the underlying mechanism for weight loss is identical.
Once-weekly injection, 0.25mg to 2mg dose range, FDA-approved for type 2 diabetes, manufactured by Novo Nordisk, available since 2017.
Ozempic is available in four dose strengths: 0.25mg, 0.5mg, 1mg, and 2mg, administered once weekly via a pre-filled injectable pen. The medication was developed by Novo Nordisk and gained FDA approval in December 2017. In the SUSTAIN clinical trial program, Ozempic demonstrated significant A1C reductions alongside meaningful weight loss, with participants losing an average of 10-15% of body weight depending on the dose. Ozempic shares its active ingredient with Wegovy but is dosed differently and carries a diabetes-specific indication.
Brand-name Ozempic® has the longest real-world track record among FDA-approved GLP-1 products, with extensive data from the SUSTAIN clinical-trial program.
Ozempic® has one of the longest real-world track records among GLP-1 medications, with FDA approval since 2017 for type 2 diabetes. Patients seeking the FDA-approved brand-name Ozempic® obtain it through a retail pharmacy on a prescription from their treating provider. Weight Method does not dispense or prescribe brand-name Ozempic®. For patients who, after consultation with a Weight Method provider, choose compounded semaglutide as part of a chronic-weight-management program, Weight Method dispenses compounded semaglutide through U.S.-licensed 503A compounding pharmacies at $154/month all-inclusive. Compounded semaglutide is not FDA-approved.
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Compounded semaglutide. Once-weekly subcutaneous injection.

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.
Speak with a licensed provider today and find out if GLP-1 medications are right for you.
Get Started NowFree consultation. No commitment.